Phesgo, a subcutaneous injection-type combination of Perjeta and Herceptin, challenges insurance coverage registration. As a result of the coverage, Phesgo of Roche Korea is presented to the Cancer Disease Review Committee of the HIRA today (30th). This is the first case of an improved anti-cancer biobetter.

Biobetter refers to drugs recognized by the Minister of the Ministry of Food and Drug Safety as having improved safety, effectiveness, and usefulness (medical compliance, convenience, etc.) compared to previously approved biological drugs, or as being progressive in pharmaceutical technology.

In the case of Phesgo, by replacing Herceptin and Perjeta, which were used for intravenous i